Bacteriophages Product Scope
Bacteriophages (Phage) are a class of viruses that specifically infect bacteria and are one of the most common organisms on Earth. Since their discovery, phages have been regarded as a potential weapon for treating bacterial infections in humans and animals due to their unique ability to "prey" on bacteria. However, with the advent of antibiotics, phage therapy has gradually fallen into disfavor. In recent years, with the increasing severity of antibiotic resistance (AMR) and the gradual weakening of the effectiveness of antibiotics, the use of phages in treatment has once again attracted attention. In addition, the widespread use of chemical disinfectants in environmental cleaning (such as fungicides in agriculture) has not only had a significant impact on the environment, but also led to the emergence of drug resistance. In view of these challenges, phages have become an effective alternative as a biological control method in fields such as farms, food processing, agriculture, aquaculture and sewage treatment. It is particularly noteworthy that phages can still effectively kill bacteria even with multidrug-resistant (MDR) bacteria, which gives phages a clear advantage in resisting drug resistance. Due to the great potential of bacteriophages in environmental sterilization, they have been proposed as hospital environmental disinfectants to prevent the spread of drug-resistant pathogens on hospital surfaces.
、
History and Current Development of the Phage Industry
Phages have a history of over a century since their discovery and were once widely used to treat bacterial infections. However, with the widespread use of antibiotics, phage therapy gradually declined worldwide, with only former Soviet Union countries and Eastern European nations, such as Russia, Georgia, and Poland, continuing to use them. Since 2019, the development of phage-based drugs and personalized therapies has accelerated. By the end of 2024, countries such as the United States, Australia, Belgium, Switzerland, France, Israel, and the United Kingdom had entered Phase 1/2 clinical trials. In Russia and Georgia, several phage-based drugs and personalized therapies have already been approved for the market. Currently, there are no phage therapy products in clinical stages in China.
Competitive Landscape of the Phage Industry
There are approximately 30 to 50 companies globally involved in the phage industry. In the former Soviet Union (Russia, Georgia), companies such as NPO Microgen, MicroMir, Biochimpharm, and Eliava BioPreparations have been producing and using phage-based drugs for years, maintaining a leading position in the application of phages in human health. In North America, companies like BiomX (Adaptive Phage Therapeutics), Armata Pharmaceuticals, Locus Biosciences, Inc., Intralytix, and Cytophage Technologies have recognized the importance of phages as an alternative to antibiotics and are accelerating the development of related drugs and personalized therapies for human health.
In China, companies such as Qingdao Noan Baite Biotechnology Co., Ltd, PrecisioBiotix, Shandong New Route Biotechnology Co., Ltd, Xiamen CANCO Biological Engineering Co., Ltd*Qingdao Run Da Biotechnology Co., Ltd, Shandong Zhongchuang Health Technology Group, and CreatiPhage. mainly focus on animal health and agricultural applications. Among them, CreatiPhage has pioneered a product pipeline for human health and environmental disinfection (already commercialized).
In Europe, companies like Phaxiam, Micreos (Phageguard), NexaBiome, and TechnoPhage are developing phage products for human health, animal health, and food safety applications. Other countries, such as Japan's RePHAGEN Co., Ltd., Turkey's Mikroliz Biotechnology, and Uruguay's Kinzbio, are emerging as new entrants into the market with startup initiatives.
Market Size of the Phage Industry
According to in-depth research by DIResearch, the global phage market is expected to reach a size of 96.59 million dollars in 2024. It is projected to grow to 354.29 million dollars by 2030, with a compound annual growth rate (CAGR) of 24.94% from 2025 to 2030.
Source: Secondary Sources, Expert Interviews and DIResearch, 2025
Future Development Trends in the Phage Industry
Multifunctional Therapies: The development trend of phages in multifunctional therapies is becoming increasingly significant, and their applications are expected to expand beyond antibacterial uses. In addition to traditional bacterial infection treatment, phages show great potential as carriers and tools in areas such as cancer immunotherapy, gene therapy, and chronic disease treatments. For example, phages can be engineered to carry specific genes or drugs, delivering therapeutic substances directly to the affected areas, thus improving treatment efficacy and reducing side effects. Additionally, the targeting ability and specificity of phages make them a promising adjunct in cancer immunotherapy, stimulating the immune system to attack tumor cells. In gene therapy, phages can serve as gene delivery vehicles to directly transfer corrective genes into patients. These multifunctional therapeutic prospects provide unprecedented opportunities for the phage industry, which is expected to further promote their widespread use in pharmaceuticals and treatments.
Precision Medicine: Phages demonstrate strong potential in the development of precision medicine, particularly in treatments tailored to individual pathological characteristics. With advancements in genomics and molecular biology, phages can be used to precisely identify specific pathogens or diseased cells, offering personalized treatment plans. This means that treatments can be customized based on the patient’s genomic information, the type of bacteria involved, and their antibiotic resistance profile, enhancing efficacy and minimizing side effects. In the future, phage therapy will incorporate specific biomarkers from patients, enabling the design of precise formulations not only for bacterial infections but also for conditions such as cancer and chronic diseases, thus creating highly personalized treatment options. As phage therapy’s targeting and customization capabilities improve, precision treatment will become an important development direction in this field, driving the advancement of medical standards.
Combination Therapy Models: The trend towards combination therapies using phages is gradually forming, especially in conjunction with traditional treatments, showing great potential. As antibiotic resistance becomes an increasingly serious issue, standalone phage therapy may not be sufficient to address complex infections or diseases. Therefore, combining phages with other treatment methods such as antibiotics, immunotherapy, and chemotherapy is emerging as a new strategy to enhance treatment efficacy. For example, phages can be combined with antibiotics to provide synergistic treatment against multidrug-resistant bacteria, enhancing antibacterial effects while reducing antibiotic usage and slowing the development of resistance. Moreover, phages show potential in cancer immunotherapy when combined with immune checkpoint inhibitors, vaccines, and other treatments, improving the immune response against tumors. The combination therapy model can integrate the targeting and selectivity of phages with the benefits of other therapies, offering patients a more comprehensive and precise treatment approach. This model is expected to become a key development direction for phage therapy in the future.
For details, please refer to the report "Global Bacteriophage Competitive Landscape Professional Research Report 2025"
Global Key Manufacturers of Bacteriophage Include:
BiomX (Adaptive Phage Therapeutics)
Armata Pharmaceuticals
Cytophage Technologies
Phaxiam
Locus
Biosciences, Inc
TechnoPhage
NPO Microgen
Qingdao Noan Baite Biotechnology Co., Ltd
MicroMir
Biochimpharm
Proteon Pharmaceuticals
iNtRON Biotechnology
PrecisioBiotix
Eliava BioPreparations
Shandong New Route Biotechnology Co., Ltd
Intralytix
Micreos (Phageguard)
Xiamen CANCO Biological Engineering Co., Ltd
Qingdao Run Da Biotechnology Co., Ltd
NexaBiome
Shandong Zhongchuang Health Technology Group
CreatiPhage
Bacteriophage Product Segment Include:
Natural Phages
Synthetic Phages
Bacteriophage Product Application Include:
Human Health
Animal Health
Agricultural Planting
Food Safety
Environmental Disinfection
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Bacteriophage Industry PESTEL Analysis
Chapter 3: Global Bacteriophage Industry Porter’s Five Forces Analysis
Chapter 4: Global Bacteriophage Major Regional Market Size and Forecast Analysis
Chapter 5: Global Bacteriophage Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Passenger Bacteriophage Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Bacteriophage Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Bacteriophage Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Bacteriophage Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Bacteriophage Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Bacteriophage Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Bacteriophage Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
DIResearch provides market research reports, focus on market segmentation research, industry research, market status and forecasts, players competition analysis, company positioning, downstream customer and product market analysis, etc. We effectively analyze complex data and information through professional methods, and finally present the research content of customer needs in the form of reports, helping companies make more valuable business decisions, helping companies improve operational efficiency and find new growth points.
